Investor Presentaiton

20 Innovative R&D - Expenditure & Major R&D Progress • • • 1H22 R&D Expenditure RMB2,399 million 1H22 R&D Expense RMB1,818 million Pharma R&D expenditure is RMB2,062 million, 14.39% of Pharma revenue. Pharma expense is RMB1,491 million, 10.41% of Pharma revenue Strong R&D capabilities with 260 ongoing pipeline projects by the end of 2021 (not including Gland Pharma's pipeline) Major R&D progress R&D Expenditure & Expense (RMB million) 22.77% YoY 1,954 16.39% YoY 2,399 1,562 1,818 R&D Expenditure R&D Expense 1H21 ■1H22 Pharma R&D Expenditure & Expense % Pharma Revenue 16.04% YoY 1,777 2,062 %Pharma Revenue 14.39% Pharma R&D Expenditure 10.41% 7.65% YoY 1,385 1.491 Pharma R&D Expense Serplulimab injection (PD-1) :1) MSI-H was approved by NMPA in March 2022; 2) the NDA of PD-1 in combination with chemotherapy in treating sqNSCLC was accepted by NMPA in September 2021; 3) the NDA of PD-1 in combination with chemotherapy in treating ES-SCLC was accepted by NMPA and SCLC was granted FDA Orphan-drug Designation in April 2022; 4) the NDA of PD-1 in combination with chemotherapy in treating ECSS was accepted by NMPA in August 2022 FS-1502 (Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection Monomethyl Auristatin F): initiated Phase 2 clinical trial in Chinese Mainland in treating NSCLC; 2) approved to enter Phase 2 clinical trial in combination with Serplulimab and/or chemotherapy in treating advanced gastric cancer with HER2 expression in Chinese Mainland FCN-159 (MEK1/2 inhibitor): 1) approved to enter Phase 2 clinical trial in Chinese Mainland in treating histiocytic tumor and arteriovenous malformation;2) ongoing Phase 2 global multi-center clinical trial in treating Neurofibromatosis type 1 Progress in 1H22: launched 2 innovative medicine/new indication (Serplulimab MSI-H indication, Rituximab RA indication); launched in total 10 generic drug/indication in Chinese Mainland and the U.S.; 1 innovative medicine/indication and 18 generic drug/indication NDA in Chinese Mainland; 14 innovative medicine/indication and 9 generic drug/indication IND in Chinese Mainland

View entire presentation